Lundbeck Archives - CDR – Chain Drug Review

AllianceRx Walgreens Prime to distribute Vyepti

May 19, 2020 by Chain Drug Review AllianceRx Walgreens Prime, Lundbeck, Tracey James Leading Headlines, Pharmacy

ORLANDO, Fla. — Lundbeck, a global pharmaceutical company specializing in brain diseases, has named AllianceRx Walgreens Prime one of only two specialty pharmacies to distribute its newest medication for the preventive treatment of migraine in adults. The medication, Vyepti (eptinezumab-jjmr), is the first and only intravenous preventive treatment for migraine. Migraine is a complex and incapacitating neurological

Takeda, Lundbeck make vortioxetine available in U.S.

June 1, 2016 by Chain Drug Review Lundbeck, Takeda Pharmaceuticals U.S.A., Trintellix, U.S. pharmacies, vortioxetine Supplier News

DEERFIELD, Ill. — Trintellix (vortioxetine), a once-daily oral antidepressant indicated for the treatment of major depressive disorder (MDD) in adults, has been rolled out to U.S. pharmacies by Takeda Pharmaceuticals U.S.A. and Lundbeck. The companies recently announced that the trade name for their vortioxetine product in this country would be changed to Trintellix to avoid